Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations-Reference-Cited by-同舟云学术

Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations

Published:2003-12-04 Issue:2 Volume:18 Page:227-232
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Drexler H G,Quentmeier H,MacLeod R A F

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2403236.pdf

Reference61 articles.

1. Drexler HG (ed). The Leukemia–Lymphoma Cell Line Facts Book. Academic Press: San Diego, 2000.

2. Drexler HG, MacLeod RAF, Borkhardt A, Janssen JWG . Recurrent chromosomal translocations and fusion genes in leukemia–lymphoma cell lines. Leukemia 1995; 9: 480–500.

3. Drexler HG, MacLeod R . Leukemia–lymphoma cell lines as model systems for hematopoietic research. Ann Med 2003; 35: 401–412.

4. Mitelman F, Johansson B, Mertens F (eds). Mitelman Database of Chromosome Aberrations in Cancer. 2003. http://cgap.nci.nih.gov/Chromosomes/Mitelman .

5. Huret JL . 11q23 rearrangements in leukaemia. Atlas Genet Cytogenet Oncol Haematol 2001. http://www.infobiogen.fr/services/chromcancer/Anomalies/11q23ID1030.html .

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Telomere Transcription in MLL-Rearranged Leukemia Cell Lines: Increased Levels of TERRA Associate with Lymphoid Lineage and Are Independent of Telomere Length and Ploidy;Biomedicines;2023-03-16

2. SGOL1-AS1 enhances cell survival in acute myeloid leukemia by maintaining pro-inflammatory signaling;Heliyon;2022-11

3. Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia;Haematologica;2022-08-25

4. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein;Molecules;2021-08-31

5. Deubiquitinating enzyme inhibitor alleviates cyclin A1‐mediated proteasome inhibitor tolerance in mixed‐lineage leukemia;Cancer Science;2021-04-05